We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Jan 21
The new facility, to be located in Watertown, Massachusetts, will manufacture viral vectors and advanced therapies
05 Nov 20
The partnership will develop advanced analytical solutions and deliver training to address the current requirements of the biopharmaceutical…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services
08 Sep 20
Alkahest is a wholly-owned subsidiary within the Grifols innovation office (GIANT) and is focused on proteins with a…
28 Aug 20
IMO is a rare, severe autosomal recessive disorder is caused due to mutations in the TCIRG1 gene, which…
25 Aug 20
Forbius develops a portfolio of selective potent inhibitors of TGF-beta 1 & 3, which mediate immunosuppression and fibrosis
18 Aug 20
Principia Biopharma is a late-stage biopharmaceutical company that develops transformative therapies for immune-mediated diseases
11 Aug 20
Ligand will pay $2 per share, valuing a total of $78m as a Contingent Value Right (CVR) in…
23 Jul 20
The US government will pay $1.95bn, after receiving of the 100 million doses, and has an option to…
17 Jul 20
The revised bid has raised the initial offer price of €39.00 per share to a new price of…
26 May 20
The acquisition will allow Roche to access Stratos Genomics’ advanced Sequencing by Expansion (SBX) chemistry, and complement the…